Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 4,968 | $17.00 | $84,456.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 30,094 | $50.61 | $1,523,057.34 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 2,789,272 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 5,710 | $50.61 | $288,983.10 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 529,173 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 29,474 | $50.61 | $1,491,679.14 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,731,817 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 61,445 | $49.69 | $3,053,202.05 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,819,366 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 11,657 | $49.69 | $579,236.33 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 534,883 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 60,179 | $49.69 | $2,990,294.51 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,761,291 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 123 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 30 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,716 Underlying: Common Stock · 123 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 181 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 29 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,560 Underlying: Common Stock · 181 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 181 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 28 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,560 Underlying: Common Stock · 181 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 434 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 27 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,744 Underlying: Common Stock · 434 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 958 | $46.24 | $44,297.92 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 22 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,887 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 123 | $39.80 | $4,895.40 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 21 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 181 | $13.22 | $2,392.82 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 20 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 181 | $10.73 | $1,942.13 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 19 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 434 | $17.00 | $7,378.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 18 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 19:31 UTC |
DiRaimondo ThomasChief Scientific Officer
|
SaleCommon Stock | 675 | $47.22 | $31,876.54 |
DisclosureSEC source: 0001415889-24-024076 · form4-09272024_110948.xml · nonDerivative · entry 2 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,938 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F4 · price: The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 19:31 UTC |
DiRaimondo ThomasChief Scientific Officer
|
SaleCommon Stock | 4,325 | $46.21 | $199,839.65 |
DisclosureSEC source: 0001415889-24-024076 · form4-09272024_110948.xml · nonDerivative · entry 1 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,613 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F2 · price: The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC |
Meyer Andrew HollmanChief Business Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · derivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,667 Underlying: Common Stock · 50,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC |
Meyer Andrew HollmanChief Business Officer
|
SaleCommon Stock | 50,000 | $45.96 | $2,297,755.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,592 F2 · price: The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC |
Meyer Andrew HollmanChief Business Officer
|
Exercise / conversionCommon Stock | 50,000 | $4.21 | $210,500.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,189 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,752 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023 and 2,834 shares acquired under the Plan on May 15, 2024. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC |
Campbell David AlanDirector · President and CEO
|
SaleCommon Stock | 795 | $47.84 | $38,031.53 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 3 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,054 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F4 · price: The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC |
Campbell David AlanDirector · President and CEO
|
SaleCommon Stock | 5,248 | $46.86 | $245,895.04 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 2 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,849 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F3 · price: The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:30 UTC |
Campbell David AlanDirector · President and CEO
|
SaleCommon Stock | 18,957 | $46.09 | $873,714.86 |
DisclosureSEC source: 0001415889-24-024074 · form4-09272024_110948.xml · nonDerivative · entry 1 Campbell David Alan · CIK 0001864158 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,097 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024. F2 · price: The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 234 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 26 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,839 Underlying: Common Stock · 234 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 345 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 25 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,741 Underlying: Common Stock · 345 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 345 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 24 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,741 Underlying: Common Stock · 345 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 828 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 23 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,178 Underlying: Common Stock · 828 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 1,826 | $46.19 | $84,342.94 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 17 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,926 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 234 | $39.80 | $9,313.20 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 16 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 345 | $13.22 | $4,560.90 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 15 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 345 | $10.73 | $3,701.85 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 14 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
Exercise / conversionCommon Stock | 828 | $17.00 | $14,076.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 13 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 1,542 | $47.74 | $73,615.08 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 12 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,880,811 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 293 | $47.74 | $13,987.82 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 11 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 546,540 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 1,511 | $47.74 | $72,135.14 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 10 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,821,470 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 46,861 | $46.42 | $2,175,287.62 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 9 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,882,353 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 8,894 | $46.42 | $412,859.48 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 8 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 546,833 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 45,894 | $46.42 | $2,130,399.48 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,822,981 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 41,661 | $47.77 | $1,990,145.97 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 2,929,214 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 7,908 | $47.77 | $377,765.16 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 555,727 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 40,803 | $47.77 | $1,949,159.31 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,868,875 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 50,539 | $46.78 | $2,364,214.42 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,970,875 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 9,592 | $46.78 | $448,713.76 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 563,635 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC |
Avalon Ventures XI, L.P.10% owner
Avalon BioVentures I, LP10% owner
Avalon BioVentures SPV I, L.P.10% owner
Lichter Jay10% owner
|
SaleCommon Stock | 49,497 | $46.78 | $2,315,469.66 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,909,678 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC |
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 391 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 12 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,682 Underlying: Common Stock · 391 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC |
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 778 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 11 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,308 Underlying: Common Stock · 778 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC |
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 778 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 10 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,308 Underlying: Common Stock · 778 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC |
Lichter Jay10% owner
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,868 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 9 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,138 Underlying: Common Stock · 1,868 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC |
Lichter Jay10% owner
|
SaleCommon Stock | 3,815 | $46.68 | $178,084.20 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 5 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.